Paratek Pharmaceuticals, Inc. (PRTK) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. boosted its position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 19.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 867,616 shares of the specialty pharmaceutical company’s stock after purchasing an additional 143,316 shares during the period. Vanguard Group Inc. owned approximately 3.14% of Paratek Pharmaceuticals worth $20,909,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its position in Paratek Pharmaceuticals by 106.8% in the second quarter. Franklin Resources Inc. now owns 508,066 shares of the specialty pharmaceutical company’s stock worth $12,244,000 after purchasing an additional 262,374 shares during the period. C WorldWide Group Holding A S lifted its position in shares of Paratek Pharmaceuticals by 449.3% during the 2nd quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock valued at $10,590,000 after acquiring an additional 359,400 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Paratek Pharmaceuticals by 275.9% during the 1st quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock valued at $7,979,000 after acquiring an additional 304,249 shares during the last quarter. Pictet Asset Management Ltd. acquired a new stake in shares of Paratek Pharmaceuticals during the 2nd quarter valued at $6,957,000. Finally, Northern Trust Corp lifted its position in shares of Paratek Pharmaceuticals by 25.9% during the 2nd quarter. Northern Trust Corp now owns 329,693 shares of the specialty pharmaceutical company’s stock valued at $7,946,000 after acquiring an additional 67,794 shares during the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Shares of Paratek Pharmaceuticals, Inc. (NASDAQ PRTK) opened at $20.13 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53. Paratek Pharmaceuticals, Inc. has a one year low of $12.55 and a one year high of $29.00.

A number of equities research analysts have recently commented on PRTK shares. HC Wainwright increased their price objective on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, July 18th. Guggenheim started coverage on Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They set a “buy” rating and a $44.00 price objective for the company. Cantor Fitzgerald set a $50.00 price objective on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 17th. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, BidaskClub downgraded Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Paratek Pharmaceuticals currently has an average rating of “Buy” and an average price target of $40.00.

TRADEMARK VIOLATION NOTICE: This story was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/11/15/paratek-pharmaceuticals-inc-prtk-shares-bought-by-vanguard-group-inc.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply